Understanding the SCADD Newborn Screening Result
At a Glance
A positive newborn screen for Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCADD) is very common, and the vast majority of babies are completely healthy. Experts now consider SCADD a harmless genetic variation rather than a disease. Most infants require no special diet or medical treatment.
Key Takeaways
- A positive newborn screen for SCADD is extremely common, and the vast majority of infants identified are completely healthy [1][2].
- Medical experts increasingly view SCADD as a harmless “biochemical entity” (a unique way the body processes certain fats) rather than a clinical disease [3][4].
- Your baby will not typically need a special diet or emergency protocols, though they should avoid the seizure medication valproic acid [5].
A positive newborn screening result for Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCADD) can be a source of immediate and intense anxiety for parents. However, modern medical research has significantly changed how doctors view this condition [4]. In the vast majority of cases, a positive screen for SCADD does not mean your baby is “sick” or will ever develop symptoms. Instead, many experts now consider SCADD to be a biochemical entity—a unique way the body processes certain fats—rather than a disease [3][4].
A Shift in Understanding
When newborn screening began, SCADD was included because it belongs to a group of disorders called fatty acid oxidation disorders, where the body has trouble breaking down fat for energy [6]. Over time, doctors noticed that nearly every infant identified with SCADD through screening remained completely healthy, with normal growth and development [1][2].
Because the biochemical “defect” rarely leads to actual health problems, many medical experts have argued that SCADD does not meet the criteria for mandatory screening [4][2]. As a result, many states and countries have removed SCADD from their primary screening panels, choosing instead to focus on conditions where early treatment is life-saving.
Most Infants Stay Healthy
The most important fact for parents is that the vast majority of infants with a positive SCADD screen will never experience any related health issues [7][8].
- Asymptomatic Growth: Most children identified via screening hit their milestones on time and have no physical or mental limitations [1][2].
- Benign Variants: Many positive results are caused by common genetic changes (specifically variants called c.625G>A and c.511C>T) that are considered harmless “polymorphisms” rather than disease-causing mutations [3][9].
Why the Screen Was Positive
The initial screen measures a marker called C4-acylcarnitine. While high levels of C4 can point to SCADD, they can also be a “false positive” or be caused by other, unrelated conditions [10][11]. To clear up the confusion, doctors use second-tier testing [9]. Your pediatrician will likely refer you to a metabolic specialist or a genetics clinic to coordinate these follow-up tests [9].
- Urine Organic Acid Profile: This test looks for a substance called ethylmalonic acid (EMA) in the urine. If the urine test is normal, the initial blood screen was likely a false alarm [9][10].
- Genetic Testing: By looking at the ACADS gene, doctors can determine if your baby has the common, harmless variants or a more rare form that might require occasional monitoring [12][7].
Next Steps for Parents
If you have received a positive result, your medical team will likely perform follow-up tests to confirm if the result is meaningful. While waiting for results:
- Feed as Normal: Most babies with SCADD do not require special diets or emergency protocols [1][13].
- Avoid Specific Medications: Some experts recommend avoiding valproic acid (a medication used for seizures), as it can interfere with how the body processes fats in people with this biochemical profile [5].
- Focus on the Child: Remember that your baby is the same healthy infant they were before the test result arrived. In the modern era of medicine, a SCADD “diagnosis” is often viewed as a piece of metabolic trivia rather than a medical crisis [4].
In this guide
4 chapters
The Biology of SCADD: ACADS, C4, and EMA
Understand the biology of SCADD. Learn how the ACADS gene works, what high C4 and EMA newborn screening markers mean, and why most babies remain healthy.
Ruling Out Look-Alike Conditions
Learn why a high C4 newborn screen for SCADD requires follow-up testing. Understand look-alike conditions like IBDD, EE, and MADD, and what tests to expect.
Symptoms and the Medical Debate
Learn the truth about Short chain acyl-CoA dehydrogenase deficiency (SCADD) symptoms. Discover why experts now consider most cases to be entirely benign.
Management, Precautions, and Follow-Up
Learn about SCADD management, precautions, and follow-up care. Understand why to avoid valproic acid and how to safely handle common childhood illnesses.
Common questions in this guide
What does a positive newborn screen for SCADD mean?
Is SCADD considered a serious disease?
Will my baby need further testing after a positive SCADD screen?
Does my baby need a special diet for SCADD?
Are there any medications my baby with SCADD should avoid?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What were the specific levels of C4-acylcarnitine on my baby's initial screen?
- 2.Does my baby have any common genetic variants, like the c.625G>A or c.511C>T variants, that are generally considered harmless?
- 3.Was the second-tier urine test (ethylmalonic acid) normal?
- 4.Are there any specific symptoms, like low blood sugar (hypoglycemia) or muscle weakness, that I should watch for, even though most babies stay healthy?
- 5.Is it necessary to see a metabolic specialist, or can we monitor my baby's growth and development with our regular pediatrician?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (13)
- 1
Clinical characteristics and related gene mutations of infants with short-chain acyl-CoA dehydrogenase deficiency by neonatal screening in Beijing.
Gong L, Yang N, Zhao J, et al.
Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 2022; (51(3)):278-283 doi:10.3724/zdxbyxb-2022-0214.
PMID: 36207829 - 2
[Clinical, biochemical and gene mutation characteristics of short chain acyl-coenzyme A dehydrogenase deficiency by neonatal screening].
Huang XW, Zhang Y, Yang JB, et al.
Zhonghua er ke za zhi = Chinese journal of pediatrics 2016; (54(12)):927-930 doi:10.3760/cma.j.issn.0578-1310.2016.12.011.
PMID: 27938594 - 3
Tread carefully: A functional variant in the human NADPH oxidase 4 (NOX4) is not disease causing.
Nafisinia M, Menezes MJ, Gold WA, et al.
Molecular genetics and metabolism 2018; (123(3)):382-387 doi:10.1016/j.ymgme.2018.01.007.
PMID: 29398271 - 4
Diverse and unselected adults with clinically relevant ACADS variants lack evidence of metabolic disease.
Breilyn MS, Kenny EE, Abul-Husn NS
Molecular genetics and metabolism 2023; (138(1)):106971 doi:10.1016/j.ymgme.2022.106971.
PMID: 36549199 - 5
Unexpected elevation in valproic acid concentration and agranulocytosis in a patient with short-chain acyl-CoA dehydrogenase deficiency.
Suzuki Y, Ito S, Otani Y, et al.
Brain & development 2021; (43(5)):657-660 doi:10.1016/j.braindev.2021.01.001.
PMID: 33549404 - 6
[An analysis of clinical characteristics and gene mutation in two patients with medium- and short-chain acyl-CoA dehydrogenase deficiency].
Tan JQ, Chen DY, Li ZT, et al.
Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2016; (18(10)):1019-1025.
PMID: 27751224 - 7
Newborn screening, genetic analysis, and long-term follow-up of 89 cases with short-chain acyl-CoA dehydrogenase deficiency (SCADD).
Qian G, Liu C, Xu Y, et al.
Molecular genetics and metabolism reports 2026; (46()):101292 doi:10.1016/j.ymgmr.2026.101292.
PMID: 41716778 - 8
Compound heterozygous mutations of ACADS gene in newborn with short chain acyl-CoA dehydrogenase deficiency: case report and literatures review.
An SJ, Kim SZ, Kim GH, et al.
Korean journal of pediatrics 2016; (59(Suppl 1)):S45-S48 doi:10.3345/kjp.2016.59.11.S45.
PMID: 28018444 - 9
Genomic Analysis of Historical Cases with Positive Newborn Screens for Short-Chain Acyl-CoA Dehydrogenase Deficiency Shows That a Validated Second-Tier Biochemical Test Can Replace Future Sequencing.
Adhikari AN, Currier RJ, Tang H, et al.
International journal of neonatal screening 2020; (6(2)) doi:10.3390/ijns6020041.
PMID: 32802992 - 10
Quantification of Differential Metabolites in Dried Blood Spots Using Second-Tier Testing for SCADD/IBDD Disorders Based on Large-Scale Newborn Screening in a Chinese Population.
Zhou W, Cai H, Li H, et al.
Frontiers in pediatrics 2021; (9()):757424 doi:10.3389/fped.2021.757424.
PMID: 34869113 - 11
Expanded Newborn Screening for Inborn Errors of Metabolism by Tandem Mass Spectrometry in Suzhou, China: Disease Spectrum, Prevalence, Genetic Characteristics in a Chinese Population.
Wang T, Ma J, Zhang Q, et al.
Frontiers in genetics 2019; (10()):1052 doi:10.3389/fgene.2019.01052.
PMID: 31737040 - 12
Clinical relevance of short-chain acyl-CoA dehydrogenase (SCAD) deficiency: Exploring the role of new variants including the first SCAD-disease-causing allele carrying a synonymous mutation.
Tonin R, Caciotti A, Funghini S, et al.
BBA clinical 2016; (5()):114-9 doi:10.1016/j.bbacli.2016.03.004.
PMID: 27051597 - 13
Retrospective analysis of isobutyryl CoA dehydrogenase deficiency.
Zhang Z, Sun Y, Wang YY, et al.
Minerva pediatrics 2024; (76(5)):645-651 doi:10.23736/S2724-5276.21.06179-6.
PMID: 34647701
This page explains SCADD newborn screening results for educational purposes only. Always consult your pediatrician or a metabolic specialist for your baby's specific follow-up care and testing.
Get notified when new evidence is published on Short chain acyl-CoA dehydrogenase deficiency.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.